Abstract:Despite the rapid advancement in the introduction of new drugs for cancer therapy, the frequent emergence of drug resistance leads to disease progression or tumor recurrence resulting in dismal prognosis. Given that genetic mutations are thought to be important drivers of anti-cancer drug resistance, it is of paramount importance to pin-point mutant genes that mediate drug resistance and elucidate the underlying molecular mechanisms in order to develop novel modalities to surmount chemoresistance and achieve more efficacious and durable cancer therapies. Cumulative evidence suggests that epigenetic alterations, especially those mediated by epigenetic enzymes with high mutation rates in cancer patients, can be a crucial factor in the development of chemoresistance. Mutant epigenetic enzymes have altered enzymatic activity which may directly or indirectly affect the level of histone modifications. This can change chromatin structure and function hence altering the expression of target genes and eventually lead to chemoresistance. In the current review, we summarize epigenetic enzyme mutations and the consequent mechanisms of drug resistance in pre-clinical drug-resistance models and relapsed cancer patient specimens. We also introduce previously unreported mutation sites in the DOT1 domain of DOT1L, which are related to lung cancer drug resistance. It is worth noting that mutations occur not only in domains with enzymatic activity but also in non-catalytic regions. Each protein domain is an evolutionarily conserved region with independent functional properties. This may provide a rationale for the potential development of small molecule inhibitors which target various functional domains of epigenetic enzymes. Finally, based on the multitude of mechanisms of drug resistance, we propose several therapeutic strategies to reverse or overcome drug-resistance phenotypes, with the aim to provide cancer patients with novel efficacious combination therapeutic regimens and strategies to improve patient prognosis.

Epithelial-Mesenchymal Transition and Drug Resistance: Role, Molecular Mechanisms, and Therapeutic Strategies

Epithelial–Mesenchymal Transition-Mediated Tumor Therapeutic Resistance

Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.

Roles of epithelial-mesenchymal transition in cancer drug resistance.

Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

Cancer drug resistance induced by EMT: novel therapeutic strategies

Research Progress on Relationship Between Epithelial-Mesenchymal Transitions and Drug Resistance in Breast Cancer

Role of Epithelial-Mesenchymal Transition in Chemoresistance in Pancreatic Ductal Adenocarcinoma

Epithelial–mesenchymal Transition Plays a Critical Role in Drug Resistance of Hepatocellular Carcinoma Cells to Oxaliplatin

Research Progress of Epithelial-mesenchymal Transition Treatment and Drug Resistance in Colorectal Cancer

Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer

Research Progress on Effects of Epithelial-mesenchymal Transition and Cancer Stem Cell on Chemotherapy Resistance

The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance

Overcoming Therapeutic Resistance to Platinum-Based Drugs by Targeting Epithelial–Mesenchymal Transition

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

Mechanistic Insights Delineating the Role of Cholesterol in Epithelial Mesenchymal Transition and Drug Resistance in Cancer

Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges

Drug resistance and Cancer stem cells

New Insights into the Epithelial-to-Mesenchymal Transition in Cancer

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance

The tumor microenvironment: a key player in multidrug resistance in cancer